Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844560 | 0.82 | KMT2A (0.41) | SIGMAR1OPRM1 | |
| SCHEMBL17865309 | 0.82 | SLC1A3 (0.47) | SIGMAR1OPRM1SLC6A3 | |
| SCHEMBL17844501 | 0.81 | SIGMAR1 (0.46) | SIGMAR1OPRM1SLC6A3HDAC4HDAC1 | |
| SCHEMBL17865225 | 0.81 | SIGMAR1 (0.42) | SIGMAR1OPRM1TMEM97HDAC4HDAC1 | |
| SCHEMBL17865306 | 0.79 | HDAC4 (0.51) | SIGMAR1OPRM1SLC6A3HDAC4HDAC1 | |
| SCHEMBL17844467 | 0.79 | SIGMAR1 (0.49) | SIGMAR1OPRM1 | |
| SCHEMBL17844461 | 0.79 | SIGMAR1 (0.47) | SIGMAR1OPRM1SLC6A3HDAC4HDAC1 | |
| SCHEMBL17844567 | 0.78 | SLC6A4 (0.42) | SIGMAR1OPRM1SLC6A3 | |
| SCHEMBL17844556 | 0.77 | SIGMAR1 (0.44) | SIGMAR1HDAC4HDAC1 | |
| SCHEMBL17844469 | 0.76 | SLC1A2 (0.46) | SIGMAR1SLC6A3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | claimed |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| WO-2016096126-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | SIGMAR1 3/4885OPRM1 2/4885TMEM97 11/4885 |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | SIGMAR1 3/4885OPRM1 2/4885TMEM97 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.